Loading organizations...

§ Private Profile · Nijmegen, Netherlands
QurieGen is a technology company.
QurieGen provides an AI-powered drug discovery platform to accelerate new treatment development. It uses proprietary single-cell genomics and data science methods to build predictive disease models, focusing on mapping cellular responses. This technology streamlines therapeutic candidate identification, particularly for oncology applications.
Founded in 2022 by Kinga Matula, QurieGen is based in Nijmegen, Netherlands. The company emerged from the insight that advanced AI and single-cell analysis could resolve traditional drug development bottlenecks. Matula envisioned a system for rapid biological data analysis, accelerating the path from discovery to medication.
QurieGen’s platform serves pharmaceutical and biotechnology firms, helping them deliver effective patient treatments faster. Its vision is to transform drug development through precision medicine, enhancing cost-effectiveness and patient outcomes. The company aims to unlock novel therapeutic avenues using its advanced single-cell AI.
QurieGen has raised $2.0M across 1 funding round.
QurieGen has raised $2.0M in total across 1 funding round.
QurieGen has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $2M Seed | — | Andreessen Horowitz, Draper Associates | Announced |
QurieGen has raised $2.0M in total across 1 funding round.
QurieGen's investors include Andreessen Horowitz, Draper Associates.
QurieGen B.V. is a Dutch biotech startup spun out from Radboud University in Nijmegen, specializing in single-cell sequencing technology to accelerate and de-risk drug discovery.[1][2][3] Its core product, QuRIE-seq, simultaneously maps transcriptome, membrane proteins, intracellular proteins, and phosphoproteins, enabling high-resolution predictive models of disease biology and drug responses through systems biology, data science, and AI.[1][2][3] The company serves pharma R&D teams by providing quantitative mode-of-action (MoA) insights across pathways and timescales, solving key challenges like understanding cellular heterogeneity, toxicity, resistance, and patient responses to streamline discovery, pre-clinical, and clinical stages.[2][3] Early growth includes pilot projects with Aduro Biotech, Janssen Pharmaceutica (J&J), and Acerta Pharma (AstraZeneca), plus a €2.2 million pre-seed raise to advance its AI-driven platform.[2][5]
QurieGen emerged as a spin-off from Radboud University, founded by a trio of experts: Dr. Eng. Kinga Matuła (CEO), Dr. Francesca Rivello (CSO), and Prof. Dr. Wilhelm Huck (board member), a serial entrepreneur behind Sphere Fluidics and Cytofind Diagnostics, and Spinoza Prize winner.[1][2] The idea stemmed from pioneering a patented single-cell method (IP filed) to capture dynamic cellular responses—overlooked by competitors lacking phosphoproteome data—pivoting from academic research to commercial pilots.[2][3] Key early traction came via paid collaborations with major pharma players like Aduro Biotech (Oss), Janssen (Beerse), and Acerta Pharma (Oss), validating its tech and fueling a €2.2 million pre-seed round in 2025 to scale AI integration.[2][5]
(Note: One source describes focus on diagnostic kits/genetic testing[4], but primary evidence confirms drug discovery platform[1][2][3][5].)
QurieGen rides the AI-systems biology wave in biotech, where single-cell multi-omics meets machine learning to tackle drug discovery's 90% failure rate amid rising costs (>$2B per drug).[3] Timing aligns with post-2020 AI booms (e.g., AlphaFold) and single-cell tech maturation, amplified by pharma's push for precision medicine amid aging populations and resistance crises.[2][3] Market tailwinds include € billions in EU DeepTech funding and demand for de-risking tools, as traditional methods falter on cellular complexity.[5] It influences the ecosystem by enabling data-driven target ID and combos, potentially cutting timelines 20-50% and fostering open biology insights via pharma partnerships.[1][2]
Next steps center on expanding paid pilots into service contracts, leveraging €2.2M to refine AI models and target high-need areas like oncology/immunology.[2][5] Trends like multimodal single-cell AI and real-world evidence integration will amplify its edge, with long-term potential in novel target discovery and patient stratification tools.[2][3] Influence may grow via more Big Pharma tie-ups or follow-on funding, evolving from service provider to platform leader—ultimately revolutionizing how we decode biology to deliver effective treatments faster.[1][3] This positions QurieGen as a high-momentum player de-risking the next drug discovery era.